How do we best detect toxic effects of drugs taken during pregnancy? A EuroMap paper

Jørn Olsen, E. Czeizel, Henrik Toft Sørensen, Gunnar Lauge Nielsen, Lolkje T W De Jong Van Den Berg, Lorentz M. Irgens, Charlotte Olesen, Lars Pedersen, Helle Larsen, Rolv T. Lie, Corinne S. De Vries, Ulf Bergman

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

It is a major clinical and public health problem that there is no clear strategy as to how we best make use of information obtained when pregnant women take drugs. For this reason, some pregnant women are not treated as they should be and some are given drugs they should not use. We suggest a monitoring system that combines some of the available datasets in Europe. Using these sources as a starting point, one can develop a system that has sufficient power to detect even rare diseases like congenital malformations and sufficient diversity to detect several possible outcomes from spontaneous abortions to childhood disorders. We also suggest that case-crossover designs should be used in case-control monitoring systems that carry a high risk of recall bias. These considerations are based upon our results from a European Union-funded concerted action called EuroMaP (Medicine and Pregnancy).

Original languageEnglish
Pages (from-to)21-32
Number of pages12
JournalDrug Safety
Volume25
Issue number1
Publication statusPublished - 2002

Fingerprint

Poisons
Pregnant Women
Pregnancy
Monitoring
Public health
Spontaneous Abortion
European Union
Medical problems
Rare Diseases
Pharmaceutical Preparations
Cross-Over Studies
Medicine
Public Health
Datasets

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Pharmacology
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Olsen, J., Czeizel, E., Sørensen, H. T., Nielsen, G. L., De Jong Van Den Berg, L. T. W., Irgens, L. M., ... Bergman, U. (2002). How do we best detect toxic effects of drugs taken during pregnancy? A EuroMap paper. Drug Safety, 25(1), 21-32.

How do we best detect toxic effects of drugs taken during pregnancy? A EuroMap paper. / Olsen, Jørn; Czeizel, E.; Sørensen, Henrik Toft; Nielsen, Gunnar Lauge; De Jong Van Den Berg, Lolkje T W; Irgens, Lorentz M.; Olesen, Charlotte; Pedersen, Lars; Larsen, Helle; Lie, Rolv T.; De Vries, Corinne S.; Bergman, Ulf.

In: Drug Safety, Vol. 25, No. 1, 2002, p. 21-32.

Research output: Contribution to journalArticle

Olsen, J, Czeizel, E, Sørensen, HT, Nielsen, GL, De Jong Van Den Berg, LTW, Irgens, LM, Olesen, C, Pedersen, L, Larsen, H, Lie, RT, De Vries, CS & Bergman, U 2002, 'How do we best detect toxic effects of drugs taken during pregnancy? A EuroMap paper', Drug Safety, vol. 25, no. 1, pp. 21-32.
Olsen J, Czeizel E, Sørensen HT, Nielsen GL, De Jong Van Den Berg LTW, Irgens LM et al. How do we best detect toxic effects of drugs taken during pregnancy? A EuroMap paper. Drug Safety. 2002;25(1):21-32.
Olsen, Jørn ; Czeizel, E. ; Sørensen, Henrik Toft ; Nielsen, Gunnar Lauge ; De Jong Van Den Berg, Lolkje T W ; Irgens, Lorentz M. ; Olesen, Charlotte ; Pedersen, Lars ; Larsen, Helle ; Lie, Rolv T. ; De Vries, Corinne S. ; Bergman, Ulf. / How do we best detect toxic effects of drugs taken during pregnancy? A EuroMap paper. In: Drug Safety. 2002 ; Vol. 25, No. 1. pp. 21-32.
@article{9ac43f1cda8442dabbaca76a8d64c128,
title = "How do we best detect toxic effects of drugs taken during pregnancy? A EuroMap paper",
abstract = "It is a major clinical and public health problem that there is no clear strategy as to how we best make use of information obtained when pregnant women take drugs. For this reason, some pregnant women are not treated as they should be and some are given drugs they should not use. We suggest a monitoring system that combines some of the available datasets in Europe. Using these sources as a starting point, one can develop a system that has sufficient power to detect even rare diseases like congenital malformations and sufficient diversity to detect several possible outcomes from spontaneous abortions to childhood disorders. We also suggest that case-crossover designs should be used in case-control monitoring systems that carry a high risk of recall bias. These considerations are based upon our results from a European Union-funded concerted action called EuroMaP (Medicine and Pregnancy).",
author = "J{\o}rn Olsen and E. Czeizel and S{\o}rensen, {Henrik Toft} and Nielsen, {Gunnar Lauge} and {De Jong Van Den Berg}, {Lolkje T W} and Irgens, {Lorentz M.} and Charlotte Olesen and Lars Pedersen and Helle Larsen and Lie, {Rolv T.} and {De Vries}, {Corinne S.} and Ulf Bergman",
year = "2002",
language = "English",
volume = "25",
pages = "21--32",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - How do we best detect toxic effects of drugs taken during pregnancy? A EuroMap paper

AU - Olsen, Jørn

AU - Czeizel, E.

AU - Sørensen, Henrik Toft

AU - Nielsen, Gunnar Lauge

AU - De Jong Van Den Berg, Lolkje T W

AU - Irgens, Lorentz M.

AU - Olesen, Charlotte

AU - Pedersen, Lars

AU - Larsen, Helle

AU - Lie, Rolv T.

AU - De Vries, Corinne S.

AU - Bergman, Ulf

PY - 2002

Y1 - 2002

N2 - It is a major clinical and public health problem that there is no clear strategy as to how we best make use of information obtained when pregnant women take drugs. For this reason, some pregnant women are not treated as they should be and some are given drugs they should not use. We suggest a monitoring system that combines some of the available datasets in Europe. Using these sources as a starting point, one can develop a system that has sufficient power to detect even rare diseases like congenital malformations and sufficient diversity to detect several possible outcomes from spontaneous abortions to childhood disorders. We also suggest that case-crossover designs should be used in case-control monitoring systems that carry a high risk of recall bias. These considerations are based upon our results from a European Union-funded concerted action called EuroMaP (Medicine and Pregnancy).

AB - It is a major clinical and public health problem that there is no clear strategy as to how we best make use of information obtained when pregnant women take drugs. For this reason, some pregnant women are not treated as they should be and some are given drugs they should not use. We suggest a monitoring system that combines some of the available datasets in Europe. Using these sources as a starting point, one can develop a system that has sufficient power to detect even rare diseases like congenital malformations and sufficient diversity to detect several possible outcomes from spontaneous abortions to childhood disorders. We also suggest that case-crossover designs should be used in case-control monitoring systems that carry a high risk of recall bias. These considerations are based upon our results from a European Union-funded concerted action called EuroMaP (Medicine and Pregnancy).

UR - http://www.scopus.com/inward/record.url?scp=0036192102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036192102&partnerID=8YFLogxK

M3 - Article

C2 - 11820910

AN - SCOPUS:0036192102

VL - 25

SP - 21

EP - 32

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 1

ER -